Tolvaptan + Placebo
Phase 2/3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-hypovolemic Non-acute Hyponatremia
Conditions
Non-hypovolemic Non-acute Hyponatremia
Trial Timeline
Jan 1, 2012 → Sep 1, 2012
NCT ID
NCT01507727About Tolvaptan + Placebo
Tolvaptan + Placebo is a phase 2/3 stage product being developed by Jiangsu Hengrui Medicine for Non-hypovolemic Non-acute Hyponatremia. The current trial status is unknown. This product is registered under clinical trial identifier NCT01507727. Target conditions include Non-hypovolemic Non-acute Hyponatremia.
Hype Score Breakdown
Clinical
15
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01507727 | Phase 2/3 | UNKNOWN |